Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial

Detalles Bibliográficos
Autores principales: Kaufman, Howard L, Andtbacka, Robert HI, Collichio, Frances A, Wolf, Michael, Li, Ai, Shilkrut, Mark, Puzanov, Igor, Ross, Merrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288773/
http://dx.doi.org/10.1186/2051-1426-2-S3-P91
Descripción
Sumario:

Ejemplares similares